For over three decades now, Ted Schroeder has worked in and around the pharmaceutical industry in the sales, marketing, and development of antibiotics. As the CEO of Nabriva Therapeutics, he has unique insights on the current development of two antibiotics which may be effective in treating community-acquired pneumonia in adults and serious urinary tract infections that do not respond to many other types of drugs.

On today’s podcast, you will learn:

• What community-acquired pneumonia is and why it can be hard to treat
• What makes gram-negative bacterial infections more challenging to treat than gram-positive bacterial infections
• How strong the clinical-based evidence is for the effectiveness of these antibiotics
• What’s to come in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents

Interested in learning more? Press play and visit https://www.nabriva.com/

Podcast: Play in new window | Download | Embed